Inflammation, Interrupted: Advancing NLRP3 inflammasome therapeutics through a novel drug discovery platform.
Location: United Kingdom, England, Little Chesterford
Employees: 11-50
Total raised: $95M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | 5AM Ventur... | 5amventure... |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.06.2020 | Series B | $55M | - |
| 26.06.2018 | Series A | $40M | 5AM Ventur... |
Mentions in press and media 17
| Date | Title | Description |
| 03.02.2026 | UK Government Embraces Activist Investment, Fuels "Picking Winners" Debate | The UK government champions an activist investment strategy. Business Secretary Peter Kyle explicitly backs "picking winners." He defends state intervention through entities like the British Business Bank. Kyle views calculated ri... |
| 30.01.2026 | Epidarex Capital Secures $145+ Million First Close For Fund IV To Invest In Life Science Startups | Epidarex Capital announced it has reached a first close of Epidarex Capital IV, LP, with more than $145 million in commitments, as the transatlantic life sciences venture firm looks to expand its company creation and early-stage investing a... |
| 08.03.2024 | NodThera says inflammation drug has positive effect in Parkinson’s | - |
| 07.03.2024 | NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial | - |
| 20.02.2024 | NodThera Touts Potential Weight Loss Effect of NLRP3 Inhibitors | - |
| 03.06.2020 | NodThera Announces Close of $55 Million Series B Financing | - |
| 03.06.2020 | NodThera Raises $55M (£44M) in Series B Financing | NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by chronic inflammation, raised $55m (£44m) in Series B financing. Novo Ventures led the round which also included... |
| 03.06.2020 | NodThera Raises $55M In Series B | CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today... |
| 03.06.2020 | NodThera Announces Close of $55 Million Series B Financing | - |
| 08.11.2019 | Cambridge companies recognised at industry leading OBN Awards 2019 event | Cambridge companies recognised at industry leading OBN Awards 2019 event 08-11-2019 Cambridge Network members Bicycle Therapeutics and Endomag have been honoured at the 2019 OBN Awards, which celebrate the best of UK life sciences. OBN (UK)... |
Show more